PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
attent a ademark Office; U.S. DEPARTMENT OF COMMERCE

der the Paperwork Reduction Act of 1995, no persons are required to resi Substitute for form 1449A/PTO	Complete if Known		
	Application Number	10/090,466	
INFORMATION DISCLOSURE	Filing Dat	03/01/02	
STATEMENT BY APPLICANT	First Named Inv nt r	Turner	
SIMILIBIAN EIGHT	Group Art Unit	1645-1646	
use as many sheets as necessary	Examiner Name	To be assigned	
Speet 0 3 2003 100 of 3	Attorney Docket Number	LEX-0315-USA	

The		3//				
,¢/20	DEMARY	detis		U.S. PATENT DOCUMEN	TS	
examiner	Cite No.'	U.S. Patent Number	Document Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
MOM	AA	4,215,051		Schroeder et al	07/29/80	
-	AB	4,376,110		David et al	03/08/83	
	AC	4,594,595		Struckman	06/10/86	
	AD	4,631,211		Houghten	12/23/86	
	AE	4,689,405		Frank et al	08/25/87	
	AF	4,713,326		Dattagupta et al	12/15/87	
	AG	4,873,191		Wagner et al	10/10/89	
	AH	4,946,778		Ladner et al	08/07/90	
	Al	5,252,743		Barrett et al	10/12/93	
	AJ	5,272,057		Smulson et al.	12/21/93	
	AK	5,424,186		Fodor et al	06/13/95	
	AL	5,445,934		Fodor et al	08/29/95	
	AM	5,459,127		Felgner et al	10/17/95	
	AN	5,556,752		Lockhart et al	09/17/96	
	AO	5,700,637		Southern	12/23/97	
	AQ	5,744,305		Fodor et al	04/28/98	
_	AQ	5,830,721		Stemmer et al	11/03/98	
	AR	5,837,458		Minshull et al	11/17/98	
	AS	5,869,336		Meyer et al.	02/09/99	THE T
	AT	5,877,397		Lonberg et al	03/02/99	
	AU	5,948,767		Scheule et al.	09/07/99	R 2
	AV	6,075,181		Kucherlapati et al	06/13/00	CE V
1	AW	6,110,490		Thierry	08/29/00	- I 0 1
MDB	AX	6,150,584		Kucherlapati et al.	11/21/00	
						600
					_	
	ļ				 	2990

Examiner	MCCYBEL	PWI	Date	6/10slox	
Signature	MCC 46C	PPL	Considered	6 (W CA	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Subs	stitute for form 1449B/PT	ro		Complete if Known		
	ADMATION	I DISC	OCUDE	Application Number	10/090,466	
	ORMATION ATEMIENT I	4 DISC	LUSUNE	Filing Dat	03/01/02	
y Sti	ATEMENT B	BY API	PLICANI	First Nam d Invent r	Turner	
	G)			Group Art Unit	1645-16 Clb	
	3 2002 e 83 many sh	eets as neces	sary)	Examiner Name	To be assigned	
%he	3	of	3	Attorney Docket Number	LEX-0315-USA	

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	_
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Ţ
CHOY AY		Bird et al, 1988, "Single-Chain Antigen-Binding Proteins", Science 242:423-426.	
1	AZ	Bitter et al, 1987, "Expression and Secretion Vectors for Yeast", Methods in Enzymology 153:516-544.	
	ВА	Colbere-Garapin et al, 1981, "A New Dominant Hybrid Selective Marker for Higher Eukaryotic Cells", J. Mol. Biol. 150:1-14.	
	ВВ	Cote et al., 1983, "Generation of human monoclonal antibodies reactive with cellular antigens," Proc. Natl. Acad. Sci. USA 80:2026-2030.	
	вс	Gautier et al, 1987, "α-DNA IV:α-anomeric and β-anomeric tetrathymidylates covalently linked to intercalating oxazolopyridocarbazole. Synthesis, physiochemical properties and poly (rA) binding", Nucleic Acids Research 15(16):6825-6641.	
	BD	Gordon, 1989, "Transgenic Animals", International Review of Cytology, 115:171-229.	
	BE	Greenspan et al, 1993, "Idiotypes: structure and immunogenicity", FASEB Journal 7:437-444.	
T	BF	Gu et al, 1994, "Deletion of a DNA Polymerase β Gene Segment in T Cells Using Cell Type-Specific Gene Targeting", Science 265:103-106.	
	BG	Huse et al, 1989, "Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda", Science 246:1275-1281.	
	вн	Huston et al, 1988, "Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli", Proc. Natl. Acad. Sci. USA 85:5879-5883.	
	ВІ	Inoue et al, 1987, "Sequence-dependent hydrolysis of RNA using modified oligonucleotide splints and R Nase H", FEBS Letters 215(2):327-330.	
	BJ	Inoue et al, 1987, "Synthesis and hybridization studies on two complementary nona(2'-O-methyl)ribonucleotides", Nucleic Acids Research 15(15):6131-6149.	
	вк	Inouye & Inouye, 1985, "Up-promoter mutations in the Ipp gene of Escherichia coli", Nucleic Acids Research 13(9):3101-3110.	
	BL	Janknecht et al, 1991, "Rapid and efficient purification of native histidine-tagged protein expressed by recombinant vaccinia virus", PNAS 88:8972-8976.	
	вм	Kohler & Milstein, 1975, "Continuous cultures of fused cells secreting antibody of predefined specificity", Nature 256:495-497.	
	BN	Lakso et al, 1992, "Targeted oncogene activation by site-specific recombination in transgenic mice", Proc. Natl. Acad. Sci. USA 89:6232-6236.	
V	во	Lavitrano et al, 1989, "Sperm Cells as Vectors for Introducing Foreign DNA into Eggs: Genetic Transformation of Mice", Cell 57:717-723.	
Mop	ВР	Lo, 1983, "Transformation by Iontophoretic Microinjection of DNA: Multiple Integrations without Tandem Insertions", Mol. 6 Cell. Biology 3(10):1803-1814.	

			72-	
Examiner Signature	Michael	PAL	Date Considered	6/25/05

TECH CENTER 1600/2900 Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). * For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. * Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Sub	stitute for form 1449B/P	то		Complete if Known		
INE	OBMATIO	N DISC	OSLIBE	Applicati n Numb r	10/090,466	
	ATEMENT		LUSUNL	Filing Date	03/01/02	
N DIA	AI BIMENI	RA WAI	PLICANI	First Named Inventor	Turner	
Ì	ري اري			Group Art Unit	1645-1646	_
JUN (3 70/454 Rsmany si	heets as necess	sary)	Examiner Name	To be assigned	
Şh	is a	of	3	Attorney Docket Number	LEX-0315-USA	
Me	1340					

חאמ	ENIT	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	_
Examin Cit er No Initials*		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
MOP BO		Logan et al, 1984, "Adenovirus tripartite leader sequence enhances translation of mRNAs late after infection", Proc. Natl. Acad. Sci. USA 81:3655-3659.	
1	BR	Lowy et al, 1980, "Isolation of Transforming DNA: Cloning the Hamster aprt Gene", Cell 22:817-823.	
	BS	Morrison et al, 1984, "Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains", Proc. Natl. Acad. Sci. USA 81:6851-6855.	
	ВТ	Mulligan & Berg, 1981, "Selection for animal cells that express the Escherichia coli gene coding for xanthine-guanine phosphoribosyltransferase", Proc. Natl. Acad. Sci. USA 78(4):2072-2076.	
	ΒU	Neuberger et al, 1984, "Recombinant antibodies possessing novel effector functions", Nature 312:604-608.	
	BV	Nisonoff, 1991, "Idiotypes: Concepts and Applications", J. of Immunology 147:2429-2438.	
	BW	O'Hare et al, 1981, "Transformation of mouse fibroblasts to methotrexate resistance by a recombinant plasmid expressing a prokaryotic dihydrofolate reductase", Proc. Natl. Acad. Sci. USA 78(3):1527-1531.	
	вх	Ruther et al, 1983, "Easy identification of cDNA clones", EMBO Journal 2(10):1791-1794.	
	BY	Santerre et al, 1984, "Expression of prokaryotic genes for hygromycin B and G418 resistance as dominant-selection markers in mouse L cells", Gene 30:147-156.	
	BZ	Sarin et al, 1988, "Inhibition of acquired immunodeficiency syndrome virus by oligodeoxynucleoside methylphosphonates", Proc. Natl. Acad. Sci. USA 85:7448-7451.	
	CA	Smith et al, 1983, "Molecular Engineering of the Autographa californica Nuclear Polyhedrosis Virus Genome: Deletion Mutations within the Polyhedrin Gene", J. Virol. 46(2):584-593.	
	СВ	Stein et al, 1988, "Physiochemical properties of phosphorothioate oligodeoxynucleotides", Nucleic Acids Research 16(8):3209-3221.	
	СС	Szybalska & Szybalski, 1962, "Genetics of Human Cell Lines, IV. DNA-Mediated Heritable Transformation of a Biochemical Trait", Proc. Natl. Acad. Sci. USA 48:2026-2034.	
	CD	Takeda et al, 1985, "Construction of chimaeric processed immunoglobulin genes containing mouse variable and human constant region sequences", Nature 314:452-454.	
	CE	Thompson et al, 1989, "Germ Line Transmission and Expression of a Corrected HPRT Gene Produced by Gene Targetin in Embryonic Stem Cells", Cell 56:313-321.	g
	CF	Van Der Putten et al, 1985, "Efficient insertion of genes into the mouse germ line via retroviral vectors", Proc. Natl. Acad. Sci. USA 82:6148-6152.	
	CG	Van Heeke et al, 1989, "Expression of Human Asparagine Synthetase in Escherichia coli", J. Biol. Chemistry 264(10):5503-5509.	
	СН	Ward et al, 1989, "Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli", Nature 341:544-546.	
V	CI	Wigler et al, 1977, "Transfer of Purified Herpes Virus Thymidine Kinase Gene to Cultured Mouse Cells", Cell 11:223-232.	
mp p	CJ	Wigler et al, 1980, "Transformation of mammalian cells with an amplifiable dominant-acting gene", Proc. Natl. Acad. Sci. USA 77(6):3567-3570.	
			-

Examiner Signature	Metrel	PML	Date Considered	6/25/05

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office Washington, DC 20231, DO NOT SEND EEES OF COMPLETED FORMS TO THIS ADDRESS OF COMPLETED FORMS TO THE TOTAL THIS ADDRESS OF COMPLETED FORMS TO THE TOTAL THIS ADDRESS OF COMPLETED FORMS TO THE TOTAL THIS ADDRESS OF CO Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents,

^{*}EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanesse patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language Translation is attached. number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

She t

Please type a plus sign (+) inside this box → □ *

Patent and Namer of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. Complete if Known Substitute for form 1449A/PTO **Application Number** 10/090.466 SUPPLEMENTAL 03/01/02 Filing Dat First Named Invent r Turner INFORMATION DISCLOSURE 1645-1646 **Group Art Unit** STATEMENT BY APPLICANT To be assigned **Examiner Name** LEX-0315-USA **Attorney Docket Number**

			U.S. PATENT DOCUMEN	TS	
Examiner Initials*	Cite No.¹	U.S. Patent Document Number Kind Code* (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A	DITE S			· · · · · · · · · · · · · · · · · · ·
,	-/-	2 2 2007 00		-	
	\				RECEIVED
		C& TRADEMAN			OCT 1 0 2002
					TECH CENTER 1600/290
					ILOH OLIVILIY 1000/10
					·
					<u> </u>
			<u> </u>		

				FORE	IGN PATENT DOCUMENTS	3		
Examiner thitials*	Cite No.¹	Foreign Patent Document			Name of Patentee or	Date of Publication of	Pages, Columns, Lines, Where Relevant	
		Office	e³ Number⁴	Kind Code ^s (if known)	Applicant of Cited Document	cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	۰ ۳
MOP	СК	wo	01/36487	АЗ	Miltenyi Biotech Inc.	05/25/01		
wol	CL	wo	01/72773	A2	Novartis AG	10/04/01		-
		├	 					+-

Examiner Signature	MICHAEL	PIOL	Date Considered	6/25/05

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. Substitute for form 1449B/PTO Complete if Known 10/090,466 **SUPPLEMENTAL** Applicati n Number 03/01/02 Filing Dat INFORMATION DISCLOSURE

First Nam d Inventor STATEMENT BY APPLICANT Group Art Unit Examiner Name To be assigned Sheet **LEX-0315-USA Attorney Docket Number**

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	_				
Examiner Initials*	Cite No. ¹						
	СМ	Database GenCore on Est. No. AA868502, NCI-CGAP, National Cancer Institute, Cancer Genome Project (CGAP), Turmor Gene Index, Gene Sequence, 01/04/99.					
	CN	International Search Report, International Application No. PCT/US02/06711, 03/01/02 (Attorney Docket No. LEX-0315-PCT)					
	•	OIP C					
	-	RECEIVED	H				
		OCT 1 0 2002	L				
		TECH CENTER 1600/2900	╀				
		TECH CENTER TOUCKSON	L				
			L				
			H				
	_		┞				
			L				
			\vdash				
			Ĺ				
			Γ				

Examiner Signature	Meins	MC	Date Considered	6/25/01	
					

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.